Menu
Washingtoner
  • Home
  • Business
  • Construction
  • Technology
  • Arts
  • Health
  • Property
  • Software
  • Real Estate
Washingtoner

Seagen to Highlight Data from Novel Targeted Therapies at AACR
Washingtoner/10106890

Trending...
  • K Spa in Bellevue Now Accepts HSA and FSA for Medically Necessary Massage Therapy
  • Spokane: Mayor Brown Announces Proposals to Jumpstart New Affordable Housing Developement
  • Consumer Accountability Alliance Issues Formal Notice Alleging Proximate Liability for Medical Harm
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that preclinical data from its pipeline of novel targeted oncology drugs will be presented at the American Association for Cancer Research (AACR) Annual Meeting being held April 10-15, 2021. The oral and poster presentations will highlight several early-stage programs utilizing Seagen's leading antibody-drug conjugate (ADC) technology as well as its proprietary sugar-engineered antibody (SEA) technology.

"Our research being presented at AACR describes intriguing preclinical data for three novel pipeline programs that are in ongoing clinical trials. This includes SEA-TGT, an anti-TIGIT antibody using our SEA technology, and two vedotin-based ADCs, SGN-B6A and SGN-STNV. We believe these three programs represent potential best-in-class or first-in-class targeted therapies for cancer," said Roger Dansey, M.D., Chief Medical Officer at Seagen. "Among the findings, we will show the enhanced therapeutic effect in combining SEA-TGT with a checkpoint inhibitor or a vedotin-based ADC across different tumor models. In addition, we will report for the first time our preclinical data with SGN-STNV, a novel ADC targeting a carbohydrate antigen that may have broad applicability across solid tumors."

Highlights of Seagen Programs Presented at AACR

SEA-TGT


Preclinical data will be presented for SEA-TGT, a novel investigational nonfucosylated human IgG1 TIGIT antibody, which utilizes Seagen's proprietary SEA technology that enhances functionality by targeting key immune activating Fc receptors. TIGIT is an inhibitory immune checkpoint that has emerged as a clinically relevant immuno-oncology target. The monotherapy and combinatorial activity of SEA-TGT was assessed and compared to TIGIT monoclonal antibodies (mAbs) with inert, standard, or effector function modified backbones in vivo and in vitro. Key preclinical findings were as follows:
  • the SEA-TGT backbone was distinct as it increased binding to activating FcγRIIIa with minimal binding to inhibitory FcγRIIb;
  • the empowered backbone had superior therapeutic properties including enhanced depletion of TIGIT-positive regulatory T-cells and activation of antigen-presenting cells both of which are important in promoting antitumor activity;
  • SEA-TGT demonstrated enhanced antitumor activity both as a single agent and in combination with anti-PD1 therapy; and,
  • SEA-TGT produced an enhanced therapeutic effect when combined with an immunogenic tumor cell death-inducing vedotin ADC.

A phase 1 trial evaluating SEA-TGT alone and in combination with anti-PD-1 therapy in patients with advanced solid tumors and select lymphomas is ongoing.

More on Washingtoner
  • Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market
  • Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
  • Spokane: National Night Out Against Crime is August 5th
  • Easton & Easton, LLP Files Suit Against The Dwelling Place Anaheim & Vineyard USA Over Abuse Allegations
  • AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic

SGN-B6A

Preclinical data will also be presented on SGN-B6A, an investigational ADC targeting integrin beta-6, which is overexpressed in numerous solid tumors and has been demonstrated to be a negative prognostic indicator across a diverse range of cancers, including non-small cell lung cancer (NSCLC). Data demonstrate SGN-B6A is active when dosed weekly in patient-derived xenograft models of NSCLC, representing both squamous and adenocarcinoma histology. A phase 1 trial evaluating monotherapy SGN-B6A in advanced solid tumors is ongoing.

SGN-STNV

SGN-STVN is an investigational ADC with a unique mechanism for targeting a carbohydrate antigen called Sialyl-Thomsen nouveau (STn), which is highly expressed on a variety of solid tumors including non-small cell lung, ovarian and gastric cancers. The preclinical data demonstrate SGN-STNV is highly specific for STn independent of protein identity, which could allow for the targeting of a range of tumor types that express different glycoproteins. In xenograft studies across key tumor types, the specificity and ability to target STn on multiple tumor-associated proteins led to durable tumor regressions. SGN-STNV was well-tolerated in in vivo studies and is being evaluated in an ongoing phase 1 study.

Additional Details of Seagen Presentations at AACR Annual Meeting 2021

All poster presentations will be available via on-demand view starting on April 10 at 8:30 a.m. Eastern Time. Oral symposium presentations will be available at the beginning of the session where the study is presented.



Abstract Title



Abstract #



Date



Presenter



Oral



Targeting Sialyl-Thomsen nouveau (STn) antigen with the SGN-STNV antibody-drug conjugate is effective in preclinical studies



#50



April 10 in session at 4:00 – 6:00 p.m. ET



A. Schwartz



E-Poster



SEA-TGT is an empowered anti-TIGIT antibody that displays superior combinatorial activity with several therapeutic agents

More on Washingtoner
  • Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
  • Spokane: Mayor Brown Urges Federal Lawmakers to Save the Community Development Block Grant (CDBG) Program
  • Colbert Packaging Announces WBENC Recognition
  • DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
  • Assent Expands Executive Team to Accelerate Global Growth & Innovation



#1583



April 10



A. Smith



Activity of SGN-B6A in patient-derived xenograft models of non-small cell lung cancer



#914



April 10



R. Lyon



Pharmacokinetics of tucatinib in healthy and hepatically-impaired volunteers



#1371



April 10



A. Topletz-Erickson


About Seagen

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company's marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

Forward-Looking Statements

Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the potential of the Company's SEA-TGT, SGN-B6A and SGN-STNV product candidates, the enhanced therapeutic effect in combining SEA-TGT with a checkpoint inhibitor or a vedotin-based ADC and the potential of the Company's pipeline. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include without limitation the difficulty and uncertainty of pharmaceutical product development, the risk of adverse events or safety signals, the inability to show sufficient efficacy in clinical trials and the possibility of adverse regulatory actions. More information about the risks and uncertainties faced by Seagen is contained under the caption "Risk Factors" included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Heritage at South Brunswick Offers Immediate Townhome Appointments and Special Mortgage Incentive Fast-Moving Sales
  • City of Spokane Announces New Deputy Police Ombuds
  • NASA Collaborative Agreement for Supply of Thin-Film Solar Tech for Orbital Application to Advance Development of Thin-Film PV Power Beaming: $ASTI
  • Exciting New Era of Sports, Entertainment & Gaming Innovation Spotlighted by Rebrand of Expanding AI Driven, Online Fan Engagement Company: SEGG Media
  • Service Ninjas Debuts First-of-Its-Kind "Membership" Platform for Home Service Pros
  • BIYA Forecasts 2025 Surge with ¥300M ($41.8 M USD) in Revenue and ¥25M Profit from Cloud Based HR Solutions: Baiya Intl. Group (N A S D A Q: BIYA)
  • Paul E. Saperstein Co. Announces Geographic Expansion of Auction Services
  • Florida Broker Bent Danholm Featured in the Daily Mail's U.S. Real Estate Coverage
  • Robin Launches Legal Intelligence Platform to solve intelligence gap in Fortune 500 legal teams
  • Melissa B. Releases Digitally Independent: Empowering Music Artists with AI and Brand Strategy
  • Consumer Accountability Alliance Issues Formal Notice Alleging Proximate Liability for Medical Harm
  • Utah Metal Fabricator Titan Forge Builds Momentum with Custom Steel Projects and Spiral Staircases
  • K Spa in Bellevue Now Accepts HSA and FSA for Medically Necessary Massage Therapy
  • Jason Koch: Pioneering the Future of Real Estate Development in New Jersey
  • Spokane: Mayor Brown Announces Proposals to Jumpstart New Affordable Housing Developement
  • Bach and Beyond: Cellists Return to the Beach for 2nd Annual Bethany Beach Cellofest
  • Spokane: False report of a shooting causes temporary delay at Riverfront Park during 4th of July celebration
  • PCL Construction Appoints Tyler Kautz to Lead Data Center Expansion Amid $1.3 Trillion Market Boom
  • NR7 Miner launches zero-cost USDT cloud mining service: daily stable income + referral rewards for double profit
  • Larry Haight's Residential Roofing Celebrates 40 Years of Excellence in the Pacific Northwest
_catLbl0 _catLbl1

Popular on Washingtoner

  • Experience Trembling Firsthand with the New AgeMan® Tremor Simulator - 230
  • ASI Accelerates iMIS® Innovation by Acquiring CSI's Product Suite and Expert Team - 191
  • Keebos Launches New Universal Pearl Strap That Attaches to Any Phone Case - 176
  • Integris Composites Joins Paris Air Show at USA Pavilion - 157
  • Last Call - Submit Your Proposal for the 2025 OpenSSL Conference in Prague - 150
  • Patrick Aloni Joins Historic Gold and Copper Discovery in Argentina with Multimillion-Dollar Stake - 133
  • Sploot Vets and DeepScan Launch Exclusive Regional U.S. Partnership to Bring Breakthrough Pet DNA Test to Market - 115
  • Evluma and LED Roadway Lighting Ltd. Join Forces to Drive Innovation - 108
  • purelyIV Blog Named One of the Top 45 IV Therapy Blogs by Feedspot
  • Exciting News: Pivotal Health Solutions Acquires Revolutionary Portable Parallel Bars

Similar on Washingtoner

  • The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
  • Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
  • Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
  • The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
  • Pyro Marketing Opens New Digital Marketing Company in Saint Petersburg to Power Growth for Fitness and Ecommerce Brands
  • Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
  • Alaska Air Group announces webcast of second-quarter 2025 financial results
  • Adostics & Genmega Announce the Introduction of A-POD
  • Erie Home Celebrates 100th Location, Cementing Coast-to-Coast Footprint
  • LIB and Nidec Rejoin Forces for Giant TH-0098 Temperature Humidity Test Chamber
Copyright © 2025 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute